+

WO2002066987A3 - Method for the determination of specific proteins and an application - Google Patents

Method for the determination of specific proteins and an application Download PDF

Info

Publication number
WO2002066987A3
WO2002066987A3 PCT/EP2002/001303 EP0201303W WO02066987A3 WO 2002066987 A3 WO2002066987 A3 WO 2002066987A3 EP 0201303 W EP0201303 W EP 0201303W WO 02066987 A3 WO02066987 A3 WO 02066987A3
Authority
WO
WIPO (PCT)
Prior art keywords
determination
specific proteins
application
eye
sample
Prior art date
Application number
PCT/EP2002/001303
Other languages
German (de)
French (fr)
Other versions
WO2002066987A2 (en
Inventor
Ralf Rotheneder
Kristina Rotheneder
Original Assignee
Cenas Ag
Ralf Rotheneder
Kristina Rotheneder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cenas Ag, Ralf Rotheneder, Kristina Rotheneder filed Critical Cenas Ag
Publication of WO2002066987A2 publication Critical patent/WO2002066987A2/en
Publication of WO2002066987A3 publication Critical patent/WO2002066987A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The method is a method for the determination of specific proteins (PK), associated with diseases such as transmittable spongiform encephalopathies (TSE), bovine spongiform encephalopathy (BSE), kuru, scrapie, Creutzfeldt-Jakob disease and similar, comprising the following steps: a) removal of parts of the eye, b) production of a sample containing the eye substance and c) carrying out a determination method for the presence of specific proteins (PK) in the sample.
PCT/EP2002/001303 2001-02-19 2002-02-08 Method for the determination of specific proteins and an application WO2002066987A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108099.9 2001-02-19
DE2001108099 DE10108099A1 (en) 2001-02-19 2001-02-19 Method for detection of specific proteins and use

Publications (2)

Publication Number Publication Date
WO2002066987A2 WO2002066987A2 (en) 2002-08-29
WO2002066987A3 true WO2002066987A3 (en) 2003-01-09

Family

ID=7674830

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001303 WO2002066987A2 (en) 2001-02-19 2002-02-08 Method for the determination of specific proteins and an application

Country Status (2)

Country Link
DE (1) DE10108099A1 (en)
WO (1) WO2002066987A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1437144A1 (en) * 2003-01-09 2004-07-14 IVPT Gmbh Rapid in-vivo test for Transmissible Spongiform Encephalopathy in the eye

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615877A (en) * 1984-02-27 1986-10-07 Savapa S.R.L. Method of determining the oxidizing activity of a biological liquid, and a corresponding reagent
WO1997037227A1 (en) * 1996-04-03 1997-10-09 Stichting Instituut Voor Dierhouderij En Diergezondheid Method for the detection of prion diseases
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19741607A1 (en) * 1997-09-20 1999-03-25 Prionics Ag New polypeptides comprising prion protein sequences
US6165784A (en) * 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
DE19918141A1 (en) * 1999-04-21 2000-10-26 Boehringer Ingelheim Vetmed Diagnosing transmissible spongiform encephalopathy, particularly before appearance of clinical symptoms, by detecting specific markers in blood cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4615877A (en) * 1984-02-27 1986-10-07 Savapa S.R.L. Method of determining the oxidizing activity of a biological liquid, and a corresponding reagent
WO1997037227A1 (en) * 1996-04-03 1997-10-09 Stichting Instituut Voor Dierhouderij En Diergezondheid Method for the detection of prion diseases
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FOSTER JAMES ET AL: "Immunolocalization of the prion protein in scrapie affected rodent retinas.", NEUROSCIENCE LETTERS, vol. 260, no. 1, 22 January 1999 (1999-01-22), pages 1 - 4, XP002214691, ISSN: 0304-3940 *
WADSWORTH J D F ET AL: "Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay", LANCET, vol. 358, no. 9277, 21 July 2001 (2001-07-21), pages 171 - 180, XP004273628, ISSN: 0140-6736 *

Also Published As

Publication number Publication date
DE10108099A1 (en) 2002-09-12
WO2002066987A2 (en) 2002-08-29

Similar Documents

Publication Publication Date Title
WO2006113915A3 (en) Ultrasensitive detection of prions by automated protein misfolding cyclic amplification
Portelius et al. Identification of novel APP/Aβ isoforms in human cerebrospinal fluid
EP1032597A4 (en) Methods for detection of prion protein as an indication of transmissible spongiform encephalopathies
Mirzaei et al. Identification of rotenone-induced modifications in α-synuclein using affinity pull-down and tandem mass spectrometry
WO2003057845A3 (en) Automated systems and methods for analysis of protein post-translational modification
WO2005121163A3 (en) Isolation of plasma or serum proteins
DE69532798D1 (en) PREPARATION OF BONES FOR TRANSPLANTATION
DE59811036D1 (en) Peptides as agonists and / or inhibitors of amyloid formation and / or cytotoxicity and for use in Alzheimer's disease, in type II diabetes mellitus and in spongiform encephalopathies
CA2405501A1 (en) A method and device for analysis of charged molecules by solution isoelectric focusing
AR071978A1 (en) SILICONE HYDROGEL CONTACT LENSES THAT PRESENT REDUCED PROTEIN ABSORPTION
NO20020190L (en) Monoclonal antibodies and antibody mixture for detection of prion protein as an indication of transmissible spongiform encephalopathies
WO2002066987A3 (en) Method for the determination of specific proteins and an application
CA2287489A1 (en) Method for labelling sample containers
WO1998035236A3 (en) Immunological assay for spongiform encephalopathies
BR0212227A (en) Fruit thinning process
NO20015094L (en) Method for diagnosing transmissible spongiform encephalopathies
Raymond et al. Purification of the pathological isoform of prion protein (PrP Sc or PrP res) from transmissible spongiform encephalopathy-affected brain tissue
Georgieva et al. Oligomerization of the proteolytic products is an intrinsic property of prion proteins
WO2002037121A3 (en) Detection of modified amino acids by mass spectrometry
WO2004065928A3 (en) Light induced immobilisation
CA2434879A1 (en) Test for transmissible spongiform encephalopathies
AUPR976401A0 (en) Agents for the treatment of alzheimer's disease and screening methods for the same
PT1435521E (en) Detection and diagnosis of transmissible spongiform encephalopathies
EP1338259A3 (en) Laser treatment apparatus
PL360139A1 (en) Antibodies capable to selectively detect prion prpsc

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载